journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Clinical Immunology

journal
https://www.readbyqxmd.com/read/29473763/statin-induced-myalgia-and-myositis-an-update-on-pathogenesis-and-clinical-recommendations
#1
Albert Selva-O'Callaghan, Marcelo Alvarado-Cardenas, Iago Pinal-Fernández, Ernesto Trallero-Araguás, José Cesar Milisenda, María Ángeles Martínez, Ana Marín, Moisés Labrador-Horrillo, Cándido Juárez, Josep María Grau-Junyent
Musculoskeletal manifestations are well-recognized side effects of treatment with statins. New advances in this field have appeared in recent years. This review focuses on the diagnosis of these conditions and their underlying pathogenesis, in particular immune-mediated necrotizing myopathy. Areas covered: Clinical phenotypes including rhabdomyolysis, myalgia and/or mild hyperCKemia, self-limited toxin statin myopathy, and immune-mediated necrotizing myopathy are herein described. Therapeutic recommendations and a diagnostic algorithm in statin-associated myopathy are also proposed...
February 23, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29465271/cd38-targeting-antibodies-in-multiple-myeloma-mechanisms-of-action-and-clinical-experience
#2
Kristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, Patty Bosman, Jhon Marin Soto, Marloes Broekmans, Richard W J Groen, Maria Themeli, Louise Nieuwenhuis, Claudia Stege, Inger S Nijhof, Tuna Mutis, Sonja Zweegman, Henk M Lokhorst, Niels W C J van de Donk
Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is refractory to immunomodulatory drugs and proteasome inhibitors. Areas covered: This review will discuss the importance of CD38-targeting antibodies for the treatment of MM patients to improve their outcome. Expert commentary: Intense immuno-oncological laboratory research has resulted in the development of functionally active monoclonal antibodies against cell surface markers present on MM cells...
February 21, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29436872/renal-transplantation-in-anti-neutrophil-cytoplasmic-antibody-vasculitis
#3
Duvuru Geetha, Sam Kant
Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) has the propensity to acquire a devastating disease course. Despite the advances in therapeutics, a significant proportion of patients progress to end-stage renal disease (ESRD). Renal transplantation is being increasingly employed in this population, with gradual improvement in outcomes over the years, however, recurrence of disease requires constant surveillance and is associated with graft failure. Areas covered: A structured literature search in PubMed and Medline and abstracts of international conferences was performed to identify cases and cohorts of AAV patients who had undergone renal transplantation for ESRD...
February 13, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29431528/targeting-the-exposome-does-correcting-vitamin-d-deficiency-have-potential-to-treat-and-prevent-asthma
#4
Paul E Pfeffer
No abstract text is available yet for this article.
February 12, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29406839/allergic-rhinitis-management-what-s-next
#5
Farnaz Tabatabaian, Thomas B Casale
Allergic rhinitis (AR) is characterized by the presence of congestion, postnasal drainage, sneezing and rhinorrhea. AR contributes to reduced productivity and significant morbidity worldwide. Areas Covered: We review data emphasizing that the most effective therapy to alter the course of AR is allergen-specific immunotherapy, either subcutaneous or sublingual. However, significant advancements in developing alternative forms of therapies have opened the door for potential novel avenues of treating patients with AR...
February 6, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29406827/pyoderma-gangrenosum-a-review-of-pathogenesis-and-treatment
#6
Christine Ahn, Deborah Negus, William Huang
Pyoderma gangrenosum (PG) is a complex neutrophilic dermatosis that can occur as an idiopathic disease, in association with systemic conditions such as inflammatory bowel disease, as part of an inherited inflammatory syndrome. It can be challenging to treat, as it occurs in a wide variety of clinical settings and there is a lack of a standardized treatment approach. The main limitations to treatment have been an incomplete understanding of the pathogenesis. However, recent advances have been made in understanding the pathogenesis of this condition, and PG is now considered an autoinflammatory disease process...
February 6, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29406811/vedolizumab-for-the-treatment-of-crohn-s-disease
#7
Marjorie Argollo, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Crohn's disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time...
February 6, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29336179/belimumab-and-antipneumococcal-vaccination-in-patients-with-systemic-lupus-erythematosus
#8
Tudor Azoicai, Sabina Antoniu, Irina Draga Caruntu, Doina Azoicai, Ileana Antohe, Cristina Gavrilovici
In systemic lupus erythematosus (SLE), flares can be caused by infections. In particular, Streptococcus pneumoniae infection can be severe or even potentially lethal in absence of previous immunization or in case of 'aggressive' systemic antibiotic therapy. Immunization efficacy, however, can be reduced in such patients with the use of the various immunosuppressive therapeutic regimens. In particular, the use of novel monoclonal antibodies against B lymphocytes raises concerns over the potential interference with antipneumococcal vaccination...
January 22, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29338551/the-regulatory-roles-of-b-cell-subsets-in-transplantation
#9
Zhulang Chu, Weilong Zou, Yanan Xu, Qiquan Sun, Yong Zhao
B cells mediate allograft rejection through antigen presentation, and production of cytokines and antibodies. More and more immunosuppressive agents specifically targeting B cells and plasma cells have been applied in clinical transplantation. However, recent studies have indicated the regulatory roles of B cells. Therefore, it is vital to clarify the different effects of B cell subsets in organ transplantation so that we can completely understand the diverse functions of B cells in transplantation. Areas covered: This review focuses on the regulatory roles of B cells in transplantation...
January 17, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29338498/from-clinical-remission-to-residual-disease-activity-in-spondyloarthritis-and-its-potential-treatment-implications
#10
Fabio Massimo Perrotta, Antonia De Socio, Silvia Scriffignano, Ennio Lubrano
Remission or low disease activity should be the target of therapy in spondyloarthritis (SpA). Due to the complexity of the disease, several composite indices that assess all disease domains were proposed to define a status of low disease activity/remission in both axial and peripheral SpA. With the introduction, in the past years, of effective biologic and targeted synthetic treatments aimed at inhibiting key cytokines and intracellular pathways, the goal of clinical remission has become an achievable target in these conditions...
January 17, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29338450/how-can-primary-care-physicians-enhance-the-early-diagnosis-of-rheumatic-diseases
#11
Christian D Mallen, Toby Helliwell, Ian C Scott
No abstract text is available yet for this article.
January 17, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29327643/adherence-to-biologics-in-patients-with-psoriasis
#12
Lauren Seale, Leah A Cardwell, Steven R Feldman
Psoriasis has a profound impact on patients' lives, but adherence to topical treatment of psoriasis is still poor. Biologic treatment has revolutionized the management of psoriasis, but adherence to treatment may still be a barrier for some patients. Areas covered: A PubMed search was conducted in August 2017 using the terms 'biologics psoriasis adherence' and 'biologics psoriasis survival.' Additional articles were obtained by perusing the references of articles identified in the original PubMed search. Articles that did not specifically mention 'survival,' 'adherence,' or 'persistence' were not included...
January 16, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29320306/disease-staging-and-sub-setting-of-interstitial-lung-disease-associated-with-systemic-sclerosis-impact-on-therapy
#13
Peter M George, Athol U Wells
Interstitial lung disease (ILD) is the most serious complication of systemic sclerosis (SSc). There is no accepted guidance as to which clinical, radiological or physiological thresholds should prompt initiation or changes in treatment. Furthermore, some patients with extensive disease remain stable without the need for intervention whilst others with limited disease at the outset, experience a precipitous decline. Areas Covered: In this article, evidence for the integration of a number of disease-specific and patient-related domains are discussed and proposed...
January 10, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29318902/interferon-%C3%AE-1a-and-%C3%AE-1b-for-patients-with-multiple-sclerosis-updates-to-current-knowledge
#14
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner, Paulus S Rommer
Although multiple sclerosis (MS) remains incurable, interferon beta (IFNβ) has been at the forefront of treatment for many years. Different formulations of IFNβ allow for different levels of exposure: low-dose/frequency with some agents, and high-dose/frequency with others. Areas covered: This review article discusses existing and emerging efficacy and safety data for IFNβ in MS. Clinical evidence of IFNβ efficacy has been generated and accumulated over many decades. During this time, key clinical trials have demonstrated the benefits of high-dose and/or high-frequency dosing of IFNβ-1a or β-1b, compared with lower levels of exposure, on outcome measures such as relapse rates, disability progression, disease progression and magnetic resonance imaging lesion outcomes...
January 10, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29300114/the-tropics-helminth-infections-and-hygiene-hypotheses
#15
Luis Caraballo
No abstract text is available yet for this article.
January 4, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29202591/venom-immunotherapy-in-patients-with-allergic-reactions-to-insect-stings
#16
Cristoforo Incorvaia, Marina Mauro, Bruna L Gritti, Eleni Makri, Erminia Ridolo
Allergy to Hymenoptera (Apis mellifera, Vespula species, Polistes species, Vespa crabro) venom can be safely and effectively treated by venom immunotherapy (VIT), which in the 40 years since its introduction has been able to prevent reactions to stings, and to treatment as well, though systemic reactions, occasionally severe, are possible. Areas covered: We reviewed the recent literature on VIT by searching in PubMed for the terms "venom immunotherapy" and "Hymenoptera venom immunotherapy" to highlight the current status of VIT and the likely development in the coming years...
December 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29202587/focussing-on-the-foot-in-psoriatic-arthritis-pathology-and-management-options
#17
Aimie Patience, Philip S Helliwell, Heidi J Siddle
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis characterised by a range of musculoskeletal conditions including enthesitis, dactylitis and synovitis as well as skin and nail manifestations. The foot is a complex mixture of tissues, all of which can be involved in this disease and is frequently the presenting feature. Areas covered: In this under-researched area, articles were reviewed from the authors' publications as well as from other known authors. This review will discuss how PsA affects the foot and ankle with a particular focus on synovitis, tenosynovitis, enthesitis, dactylitis, bone erosion and psoriatic skin and nail disease...
December 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29303368/imatinib-for-the-treatment-of-hypereosinophilic-syndromes
#18
Grzegorz Helbig
Hypereosinophilic syndromes (HES) encompass a group of disorders defined by sustained peripheral blood hypereosinophilia >1500/mm 3 and evidence of eosinophilia-associated organ impairment. Approximately 10% of HES patients may harbor a cryptic deletion on chromosome 4 leading to formation of the FIP1L1-PDGFRA (F/P) fusion gene; these patients are diagnosed as F/P-mutated myeloid/lymphoid neoplasms with eosinophilia (MLN-eo). Areas covered: This review discusses the results of IM treatment in HES depending on mutation status...
February 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29300535/hematopoietic-cell-transplantation-in-primary-immunodeficiency-conventional-and-emerging-indications
#19
Mary A Slatter, Andrew R Gennery
Hematopoietic stem cell transplantation (HSCT) is an established curative treatment for many primary immunodeficiencies. Advances in donor selection, graft manipulation, conditioning and treatment of complications, mean that survival for many conditions is now around 90%. Next generation sequencing is identifying new immunodeficiencies, many of which are treatable with HSCT. Challenges remain however with short and long-term sequalae. This article reviews latest developments in HSCT for conventional primary immunodeficiencies and presents data on outcome for emerging diseases, Areas covered: This article reviews recently published literature detailing advances, particularly in conditioning regimens and new methods of T-lymphocyte depletion, as well as new information regarding approach and out come of transplanting patients with conventional primary immunodeficiencies...
February 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29297701/antirheumatic-biologics-in-pregnant-patients-a-call-for-studies-to-address-the-knowledge-gap
#20
Monika Østensen
No abstract text is available yet for this article.
February 2018: Expert Review of Clinical Immunology
journal
journal
41324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"